Covid-19 Research

Original Article

Molecular Diversity and Characteristics of KRAS Mutations in Colorectal Cancers

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Original Article
Subject Medicine Group
OCLC JBRES Record
Amrit Kaur Kaler*, Omkar Dharut, Smitha Umarji, Shweta Limaye, Bijal Kulkarni, Meenal Hastak, Nivetha Athikari, Yash Tiwarekar, Samrudhi Rane, Ankita Nikam, Imraan Sheikh and Sandeep Goyle
Issue: Volume4-Issue1
Pages: 077-083
Received: 2023-01-18
Accepted: 2023-01-21
Published: 2023-01-24

Abstract

Background: KRAS oncogene is involved in colorectal carcinogenesis in 22 to 45% of cases. KRAS mutations can render Epidermal Growth Factor Receptor (EGFR) inhibitors ineffective. The present study is aimed to determine the molecular diversity, frequency, and characteristics of KRAS mutations in metastatic Colorectal Cancer (mCRC). The gene KRAS contains 4 coding exons and 1 non-coding exon, of which exon 2 has the highest mutation rate, which is directly associated with the occurrence of poor prognosis and drug resistance. Codon 12, 13, 61 are common KRAS mutations. The most prevalent KRAS mutation observed was codon 12-G12D mutation where Glycine is changed to Aspartic acid.

Materials and Methods: A retrospective study was conducted on both in-situ and metastatic colorectal cancers that were registered for KRAS gene mutation testing in Department of Molecular Pathology and Genomics, Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, from January 2016 to January 2022. KRAS mutations studies were carried out in primary and metastatic 87 patients of colorectal cancers. The samples contained 37 women aged 25-80 years and 50 men aged 29-77 years. Formalin fixed and paraffin embedded tissue samples were evaluated using Sanger sequencing and statistical analysis was carried out.

Results: KRAS mutations were demonstrated in 26 cases of 87 patients (29.88%). Of the 26 cases, the substitution nucleotide variations as point mutations were as follows: Codon 12-18 cases (69%), codon 13-4 cases (15%), codon 61-2 cases (8%), codon 146-1 case (4%), and codon 10-1 case (4%). The Codon 12 mutations were detected as follows: G12D-9 cases (50%), G12V-3 cases (17%), G12A-3 cases (17%), G12S-2 cases (11%), G12C-1 case (5%); Codon 13 showed all 4 mutations (4%) in G13D. KRAS mutations were found to be more frequent in elderly age group. Most m-KRAS tumors were located in sigmoid colon and rectum (left sided/distal colon), although, the mutations were spread across including ascending colon (right sided/proximal colon) and rarely in jejunum too. The TNM stage showed majority (50%) of KRAS mutations in stage IV, and 20% of cases in stage II and III each.

Conclusion: In this series, 29% of colorectal cancer tissue samples had KRAS mutations. Their frequency and distribution showed majority mutations on left sided/distal colon, elderly population, more common in females and presented at an advanced stage. There was no clinicopathological significance to histomorphology. Understanding KRAS mutations in different aspects can give a better comprehensive understanding of KRAS associated CRCs.

FullText HTML FullText PDF DOI: 10.37871/jbres1650 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2023 Kaler AK, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Kaler AK, Dharut O, Umarji S, Limaye S, Kulkarni B, Hastak M, Athikari N, Tiwarekar Y, Rane S, Nikam A, Sheikh I, Goyle S. Molecular Diversity and Characteristics of KRAS Mutations in Colorectal Cancers. 2023 Jan 24; 4(1): 077-083. doi: 10.37871/jbres1650, Article ID: JBRES1650, Available at: https://www.jelsciences.com/ articles/jbres1650.pdf

Subject area(s)

OncologyCancer

References

  1. Patil PS, Saklani A, Gambhire P, Mehta S, Engineer R, De'Souza A, Chopra S, Bal M. Colorectal Cancer in India: An Audit from a Tertiary Center in a Low Prevalence Area. Indian J Surg Oncol. 2017 Dec;8(4):484-490. doi: 10.1007/s13193-017-0655-0. Epub 2017 Apr 22. PMID: 29203978; PMCID: PMC5705504.
  2. Inoue Y, Saigusa S, Iwata T, Okugawa Y, Toiyama Y, Tanaka K, Uchida K, Mohri Y, Kusunoki M. The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Rep. 2012 Nov;28(5):1579-84. doi: 10.3892/or.2012.1974. Epub 2012 Aug 21. PMID: 22922794.
  3. Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol. 2012 Oct 7;18(37):5171-80. doi: 10.3748/wjg.v18.i37.5171. PMID: 23066310; PMCID: PMC3468848.
  4. Harlé A, Filhine-Tresarrieu P, Husson M, Boidot R, Rouyer M, Dubois C, Leroux A, Merlin JL. Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing. Target Oncol. 2016 Jun;11(3):363-70. doi: 10.1007/s11523-015-0404-7. PMID: 26661077.
  5. Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. Gastroenterology Res. 2018 Aug;11(4):264-273. doi: 10.14740/gr1062w. Epub 2018 Feb 8. PMID: 30116425; PMCID: PMC6089587.
  6. Etienne-Grimaldi MC, Formento JL, Francoual M, François E, Formento P, Renée N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008 Aug 1;14(15):4830-5. doi: 10.1158/1078-0432.CCR-07-4906. PMID: 18676755.
  7. Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. J Natl Cancer Inst. 2016 Dec 31;109(5):djw272. doi: 10.1093/jnci/djw272. PMID: 28040692; PMCID: PMC6075212.
  8. Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA, Zali MR. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench. 2013 Summer;6(3):120-8. PMID: 24834258; PMCID: PMC4017514.
  9. Müller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016 Aug;469(2):125-34. doi: 10.1007/s00428-016-1956-3. Epub 2016 Jun 20. PMID: 27325016; PMCID: PMC4978761.
  10. Yamane L, Scapulatempo-Neto C, Reis RM, Guimarães DP. Serrated pathway in colorectal carcinogenesis. World J Gastroenterol. 2014 Mar 14;20(10):2634-40. doi: 10.3748/wjg.v20.i10.2634. PMID: 24627599; PMCID: PMC3949272.
  11. Inamura K. Colorectal Cancers: An Update on Their Molecular Pathology. Cancers (Basel). 2018 Jan 20;10(1):26. doi: 10.3390/cancers10010026. PMID: 29361689; PMCID: PMC5789376.
  12. Charlton ME, Kahl AR, Greenbaum AA, Karlitz JJ, Lin C, Lynch CF, Chen VW. KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013. J Natl Compr Canc Netw. 2017 Dec;15(12):1484-1493. doi: 10.6004/jnccn.2017.7011. PMID: 29223986; PMCID: PMC7458121.
  13. Heinemann V vWL, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol. 2014;32:5s(suppl; abstr 3600).
  14. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29. PMID: 27358379; PMCID: PMC4999563.
  15. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4. PMID: 34096690; PMCID: PMC9116274.
  16. Lenz, Heinz-Josef, et al. "A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)." (2022): 100-100.
  17. Lhermitte B, Egele C, Weingertner N, Ambrosetti D, Dadone B, Kubiniek V, Burel-Vandenbos F, Coyne J, Michiels JF, Chenard MP, Rouleau E, Sabourin JC, Bellocq JP. Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment. Virchows Arch. 2017 Jan;470(1):21-27. doi: 10.1007/s00428-016-2042-6. Epub 2016 Nov 16. PMID: 27853865.
  18. Sanger Sequencing: Introduction, Principle, and Protocol | CD Genomics Blog. 2022.
  19. Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol. 2010;2010:150960. doi: 10.1155/2010/150960. Epub 2010 Jun 7. PMID: 20617134; PMCID: PMC2896632.
  20. Anderson MW, Reynolds SH, You M, Maronpot RM. Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect. 1992 Nov;98:13-24. doi: 10.1289/ehp.929813. PMID: 1486840; PMCID: PMC1519627.
  21. Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.
  22. Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst. 2012 Dec 5;104(23):1785-95. doi: 10.1093/jnci/djs433. Epub 2012 Nov 28. PMID: 23197490; PMCID: PMC3514165.
  23. Yamane LS, Scapulatempo-Neto C, Alvarenga L, Oliveira CZ, Berardinelli GN, Almodova E, Cunha TR, Fava G, Colaiacovo W, Melani A, Fregnani JH, Reis RM, Guimarães DP. KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy. Oncol Rep. 2014 Oct;32(4):1419-26. doi: 10.3892/or.2014.3338. Epub 2014 Jul 18. PMID: 25050586.
  24. Veldore VH, Rao MR, Prabhudesai SA, Tejaswi R, Kakara S, Pattanayak S, Krishnamoorthy N, Tejaswini BN, Hazarika D, Gangoli A, Rahman SM, Dixit J, Naik R, Diwakar RB, Satheesh CT, Shashidhara HP, Patil S, Gopinath KS, Kumar BS. Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. Indian J Cancer. 2014 Oct-Dec;51(4):531-7. doi: 10.4103/0019-509X.175371. PMID: 26842186.
  25. Ozer M, Goksu SY, Sanford NN, Ahn C, Beg MS, Ali Kazmi SM. Age-dependent prognostic value of KRAS mutation in metastatic colorectal cancer. Future Oncol. 2021 Dec;17(35):4883-4893. doi: 10.2217/fon-2021-0650. Epub 2021 Nov 11. PMID: 34758634; PMCID: PMC8890131.
  26. Sirisena ND, Deen K, Mandawala DEN, Herath P, Dissanayake VHW. The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka. BMC Res Notes. 2017 Aug 10;10(1):392. doi: 10.1186/s13104-017-2731-5. PMID: 28797274; PMCID: PMC5553606.
  27. Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, Punt CJ, Nagtegaal ID. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011 Mar 15;104(6):1020-6. doi: 10.1038/bjc.2011.26. Epub 2011 Mar 1. PMID: 21364579; PMCID: PMC3065268.
  28. He K, Wang Y, Zhong Y, Pan X, Si L, Lu J. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. Onco Targets Ther. 2020 Dec 8;13:12601-12613. doi: 10.2147/OTT.S279312. PMID: 33335401; PMCID: PMC7737549.
  29. Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, Rousseau A, Mountford R, McWhirter D, Malik HZ. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017 Mar 28;116(7):923-929. doi: 10.1038/bjc.2017.37. Epub 2017 Feb 16. PMID: 28208157; PMCID: PMC5379149.
  30. Baskin Y, Dagdeviren YK, Calibasi G, Canda AE, Sarioglu S, Ellidokuz H, Oztop I. KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas. J Gastrointest Oncol. 2014 Aug;5(4):265-9. doi: 10.3978/j.issn.2078-6891.2014.038. PMID: 25083299; PMCID: PMC4110495.
  31. Xie MZ, Li JL, Cai ZM, Li KZ, Hu BL. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value. BMC Gastroenterol. 2019 Mar 27;19(1):46. doi: 10.1186/s12876-019-0965-5. PMID: 30917791; PMCID: PMC6437985.
  32. Watanabe T, Yoshino T, Uetake H, Yamazaki K, Ishiguro M, Kurokawa T, Saijo N, Ohashi Y, Sugihara K. KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol. 2013 Jul;43(7):706-12. doi: 10.1093/jjco/hyt062. Epub 2013 May 8. PMID: 23657052.
  33. Bollag G, Adler F, elMasry N, McCabe PC, Conner E Jr, Thompson P, McCormick F, Shannon K. Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J Biol Chem. 1996 Dec 20;271(51):32491-4. doi: 10.1074/jbc.271.51.32491. PMID: 8955068.
  34. Tong JH, Lung RW, Sin FM, Law PP, Kang W, Chan AW, Ma BB, Mak TW, Ng SS, To KF. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther. 2014 Jun 1;15(6):768-76. doi: 10.4161/cbt.28550. Epub 2014 Mar 18. PMID: 24642870; PMCID: PMC4049792.
  35. Huang, L., Guo, Z., Wang, F. et al. KRAS mutation: from undruggable to druggable in cancer. Sig Transduct Target Ther 6, 386 (2021).
  36. https://doi.org/10.1038/s41392-021-00780-4
  37. .
  38. Parikh, K., Banna, G., Liu, S.V. et al. Drugging KRAS: current perspectives and state-of-art review. J Hematol Oncol 15, 152 (2022).
  39. Janne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med. 2022;387(2):120–31.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership